Deal for Parkinson pair
Brussels – Biopharma giant UCB Group has secured exclusive rights to two drug candidates for treating Parkinson’s disease from Swiss drug developer Synosia Therapeutics AG. Synosia will receive an undisclosed upfront payment and is eligible for up to US$ 725m (EUR517m) in milestones plus royalties. The Swiss firm will be responsible for Phase II development, while UCB will take on Phase III development and commercialisation. UCB led the financing with a US$ 20m (EUR14.3m) investment. SYN-115 is an adenosine A2A receptor inhibitor Synosia obtained from Hoffmann-La Roche (Basel) three years ago. It is designed to work as an oral pill with the rare ability to cross the blood-brain barrier. The second candidate is SYN-118, a 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor. The two drug candidates are both currently in Phase II testing for PD. With the deal, UCB wants to further strengthen its neurology portfolio.